Literature DB >> 33673151

Clinical Analysis of Early-Stage Pancreatic Cancer and Proposal for a New Diagnostic Algorithm: A Multicenter Observational Study.

Juri Ikemoto1, Masahiro Serikawa1, Keiji Hanada2, Noriaki Eguchi3, Tamito Sasaki4, Yoshifumi Fujimoto5, Shinichiro Sugiyama6, Atsushi Yamaguchi7, Bunjiro Noma8, Michihiro Kamigaki9, Tomoyuki Minami10, Akihito Okazaki11, Masanobu Yukutake12, Yasutaka Ishii1, Teruo Mouri13, Akinori Shimizu2, Tomofumi Tsuboi1, Koji Arihiro14, Kazuaki Chayama1.   

Abstract

Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is challenging but essential for improving its poor prognosis. We established a multicenter study to clarify the clinicopathological features, and to propose new algorithm for early diagnosis of PDAC. Ninety-six patients with stage 0 and IA PDAC were enrolled from 13 high-volume centers. Overall, 70% of the patients were asymptomatic. The serum pancreatic enzyme levels were abnormal in half of the patients. The sensitivity of endoscopic ultrasonography (EUS) for detecting small PDAC was superior to computed tomography and magnetic resonance imaging (MRI) (82%, 58%, and 38%, respectively). Indirect imaging findings were useful to detect early-stage PDAC; especially, main pancreatic duct stenosis on MRI had the highest positive rate of 86% in stage 0 patients. For preoperative pathological diagnosis, the sensitivity of endoscopic retrograde cholangiopancreatography (ERCP)-associated pancreatic juice cytology was 84%. Among the stage IA patients, EUS-guided fine-needle aspiration revealed adenocarcinoma in 93% patients. For early diagnosis of PDAC, it is essential to identify asymptomatic patients and ensure close examinations of indirect imaging findings and standardization of preoperative pathological diagnosis. Therefore, a new diagnostic algorithm based on tumor size and imaging findings should be developed.

Entities:  

Keywords:  early diagnosis; endoscopic retrograde cholangiopancreatography; endoscopic ultrasonography; multicenter study; pancreatic ductal adenocarcinoma

Year:  2021        PMID: 33673151     DOI: 10.3390/diagnostics11020287

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  4 in total

Review 1.  Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer.

Authors:  Debra Rivera
Journal:  Metabolites       Date:  2022-04-30

2.  Diagnostic Strategy of Early Stage Pancreatic Cancer via Clinical Predictor Assessment: Clinical Indicators, Risk Factors and Imaging Findings.

Authors:  Ryota Sagami; Takao Sato; Kazuhiro Mizukami; Mitsuteru Motomura; Kazuhisa Okamoto; Satoshi Fukuchi; Yuichiro Otsuka; Takashi Abe; Hideki Ono; Kei Mori; Kurato Wada; Tomoyuki Iwaki; Hidefumi Nishikiori; Koichi Honda; Yuji Amano; Kazunari Murakami
Journal:  Diagnostics (Basel)       Date:  2022-02-01

Review 3.  Early diagnosis of pancreatic cancer: What strategies to avoid a foretold catastrophe.

Authors:  Valeria Tonini; Manuel Zanni
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

4.  Clinical features and prognostic impact of asymptomatic pancreatic cancer.

Authors:  Tetsuya Takikawa; Kazuhiro Kikuta; Shin Hamada; Kiyoshi Kume; Shin Miura; Naoki Yoshida; Yu Tanaka; Ryotaro Matsumoto; Mio Ikeda; Fumiya Kataoka; Akira Sasaki; Kei Nakagawa; Michiaki Unno; Atsushi Masamune
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.